Adams, Harkness & Hill upgraded its rating on Martek Biosciences (MATK) to Strong Buy and reiterated its $28 price target. It is forecasting 100 percent revenue growth in 2001 and 150 percent in 2002 based on new licensees in the U.S. market for the company’s EFA products for use in baby formulas.
Tucker Anthony Sutro Markets downgraded NBTY Inc. from Strong Buy to Buy with a $13 target price and advised clients to buy on further weakness. It noted that it would tentatively lower FY02 EPS from $.92 to $.75 until the release of 4Q01 results on Nov. 5.